VicrivirocOther Names: MK-4176, MK-4176 IVR, MK-4176 intravaginal ring, MK-7690, SCH-417690, SCH-D, VCV, vicriviroc IVR, vicriviroc intravaginal ring, vicriviroc maleate Drug Class: CCR5 Antagonist Molecular Formula: C28 H38 F3 N5 O2 Registry Number: 306296-47-9 (CAS) Chemical Name: (4,6-dimethylpyrimidin-5-yl)-[4-[(3S)-4-[(1R)-2-methoxy-1-[4-(trifluoromethyl)phenyl]ethyl]-3-methyl-piperazin-1-yl]-4-methyl-1-piperidyl]methanone Chemical Class: Pyrimidines Organization: Merck & Co., Inc. Phase of Development: Vicriviroc for HIV treatment was previously in Phase III studies but has since been discontinued. Vicriviroc-containing microbicides for HIV prevention are in Phase I development.
(Compound details obtained from ChemIDplus Advanced,1 NIAID Therapeutics Database,2 National AIDS Treatment Advocacy Project [NATAP] website,3 ClinicalTrials.gov,4,5 and Clinical Pharmacokinetics article.6)
What is an investigational drug?
Anis one that is under study and is not approved by the U.S. (FDA) for sale in the United States. Medical research studies are conducted to evaluate the safety and effectiveness of an investigational drug. These research studies are also called clinical trials. Once an investigational drug has been proven safe and effective in clinical trials, FDA may approve the drug for sale in the United States.
To learn more about investigational drugs, read the What is an Investigational HIV Drug? fact sheet.
What is vicriviroc?
Vicriviroc is an investigational drug that was first studied for the treatment of HIV
Currently, vicriviroc-containing microbicides to prevent of HIV infection in women are being studied in early clinical trials.4,5 Topical microbicides are products that are applied to the vagina or rectum (such as gels, films, or creams) or inserted into the vagina (such as vaginal rings) to prevent getting sexually transmitted infections, such as HIV infection.7,8
Vicriviroc belongs to a class (group) of HIV drugs called .6 CCR5 antagonists work by attaching to a antagonists on the surface of the immune cells. The protein is called the CCR5 co- . When vicriviroc attaches to the CCR5 co-receptor, certain strains of HIV—called —cannot attach to, enter, or infect the cell.9 This prevents HIV from multiplying and can reduce the amount of HIV in the body.
How are clinical trials of investigational drugs conducted?
Clinical trials are conducted in “phases.” Each phase has a different purpose and helps researchers answer different questions.10
- Phase I trials: Researchers test an investigational drug in a small group of people (20–80) for the first time. The purpose is to evaluate its safety and identify side effects.
- Phase II trials: The investigational drug is administered to a larger group of people (100–300) to determine its effectiveness and to further evaluate its safety.
- Phase III trials: The investigational drug is administered to large groups of people (1,000–3,000) to confirm its effectiveness, monitor side effects, compare it with standard or equivalent treatments, and collect information that will allow the investigational drug to be used safely.10
In most cases, an investigational drug must be proven effective and must show continued safety in a Phase III to be considered for approval by FDA for sale in the United States. Some drugs go through FDA’s accelerated approval process and are approved before a Phase III clinical trial is complete. After a drug is approved by FDA and made available to the public, researchers track its safety in Phase IV trials to seek more information about the drug’s risks, benefits, and optimal use.10
Some clinical trials are categorized as “a” or “b,” such as “Phase Ia” or “Phase IIb.” These different subphases typically mean that a study is researching certain types of information or using a certain type of participant population.
In what phase of testing is vicriviroc?
Vicriviroc for HIV treatment has been studied in Phase III clinical trials.2 The development of vicriviroc for the treatment of HIV infection was discontinued in July 2010.3
Vicriviroc-containing topical microbicides to prevent sexualof HIV infection in women have been studied in Phase I clinical trials.4,5
What are some studies on vicriviroc?
The study of oral vicriviroc for HIV treatment was discontinued in 2010. The company developing the drug announced that this decision was based on data from a Phase II trial in adults who had never taken HIV medicines before and 2 Phase III trials in adults who had previous experience with . ( therapy, or ART, is the recommended treatment for HIV infection and involves using a combination of different antiretroviral [ARV] drugs to prevent HIV from replicating.) In these trials, vicriviroc was not shown to be more effective than currently approved HIV medicines already in use.3,11,12
Study Names: P04875; NCT00551018
Sponsor: Merck Sharp & Dohme Corp.
Status: This study has been completed.
Location: Not available
- Participants were adults with HIV who had never been on ART before entering the study, or had been on ART for 4 weeks or less (with exceptions). None of the participants had received ART for 8 weeks before entering the study.
- All participants had R5-tropic HIV ( that uses CCR5 as a co-receptor).
- Participants had levels of 2,000 copies/mL or more. (Viral load is the amount of HIV in a blood sample.)
- Participants had CD4 cell counts of 100 cells/mm3 or less. (A is a laboratory test that measures the number of CD4 cells in a sample of blood and is an important indicator of immune function.)
Purpose: The purpose of this study was to compare vicriviroc's safety and effectiveness to that of the FDA-approved combination drug emtricitabine/tenofovir disoproxil fumarate (brand name: Truvada). The researchers evaluated the effects of the drugs after 48 weeks and 96 weeks of treatment.13
Study Names: (1) VICTOR-E3; P04405AM5; NCT00523211 and (2) VICTOR-E4; P04889AM8; NCT00474370
Sponsor: Merck Sharp & Dohme Corp.
Status: These studies have been completed.
Location: North and South America, Europe, and South Africa
- Participants were people with HIV who were 16 years of age and older and who had taken HIV medicines before entering the study.
- All participants had R5-tropic HIV.
- Participants had viral loads greater than 1,000 copies/mL within 60 days of the start of the study.
- Before the study started, participants had been on ART that included 3 or more ARVs for at least 4 weeks and had had no changes to their ART, or they had received no ART for at least 4 weeks.
- Participants had ritonavir, brand name: Norvir). to at least 2 ARV drug classes ( [NRTI], [NNRTI], or [PI]) or had taken at least 6 months of ART that included at least 2 of the following: 1 NRTI, 1 NNRTI, or 2 PIs (excluding a low of
Purpose: VICTOR-E3 and VICTOR-E4 were identical studies that compared the safety and effectiveness of vicriviroc to a . (A placebo is an inactive drug that is identical in appearance to the active drug being studied.)14,15
Vicriviroc is being developed into products to prevent sexually acquired HIV infection in women. Two Phase I studies looked at the safety and drug properties of rings (IVRs) containing vicriviroc.4,5
MTN-027; NCT02356302: This study evaluated 3 IVRs: one containing vicriviroc, one containing MK-2048 (an investigational inhibitor), and one a combination IVR containing both vicriviroc and MK-2048. (The combination IVR is also known as MK-2048A.) Each of the 3 IVRs were compared to a placebo IVR.4
MTN-028; NCT02419456: This study evaluated the combination IVR (MK-2048A) at 2 different dose strengths.5
What side effects might vicriviroc cause?
One goal of HIV research is to identify new drugs that have fewer side effects. The following side effects were observed in the treatment studies of vicriviroc listed above.
VICTOR-E3 (NCT00523211) and VICTOR-E4 (NCT00474370): In these Phase III studies, side effects were similar in both the vicriviroc and placebo groups. But, compared to the placebo group, more participants in the vicriviroc group quit the study because of side effects.16
Clinical trials of intravaginal rings containing vicriviroc are just beginning. As testing of intravaginal rings containing vicriviroc continues, information on possible side effects will be gathered.
Where can I get more information about clinical trials studying vicriviroc?
More information about vicriviroc-related research studies is available from the AIDSinfo database of study summaries. Click on the title of any trial in the list to see the ClinicalTrials.gov trial summary and more information about the study.
How can I find more information about participating in a clinical trial?
Participating in a clinical trial can provide benefits. For example, a volunteer participant can benefit from new research treatments before they are widely available. Participants also receive regular and careful medical attention from a research team that includes doctors and other health professionals. However, clinical trials may also involve risks of varying degrees, such as unpleasant, serious, or even life-threatening side effects from the treatment being studied.10
Your health care provider can help you decide whether participating in a clinical trial is right for you. For more information, visit NIH Clinical Research Trials and You.
- United States National Library of Medicine. ChemIDplus Advanced. Available at: https://chem.nlm.nih.gov/chemidplus/rn/306296-47-9. Last accessed on January 31, 2018.
- National Institute of Allergy and Infectious Diseases (NIAID). NIAID ChemDB, HIV Drugs in Development. Available at: https://chemdb.niaid.nih.gov/DrugDevelopmentHIV.aspx. Last accessed on January 31, 2018.
- Dunkle LM. Merck Research Laboratories. Vicriviroc discontinued investigator letter. National AIDS Treatment Advocacy Project (NATAP): News Updates; 2010. Available at: http://www.natap.org/2010/newsUpdates/071510_02.htm. Last accessed on January 31, 2018. [Archived at WebCite]
- National Institute of Allergy and Infectious Diseases (NIAID). Phase 1 safety and pharmacokinetics study of MK-2048/vicriviroc (MK-4176)/MK-2048A intravaginal rings. In: ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). Registered on February 2, 2015. NLM Identifier: NCT02356302. Available at: https://www.clinicaltrials.gov/ct2/show/NCT02356302. Last accessed on January 31, 2018.
- National Institute of Allergy and Infectious Diseases (NIAID). Phase 1 pharmacokinetic trial of two intravaginal rings (IVRs) containing different dose strengths of vicriviroc (MK-4176) and MK-2048. In: ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). Registered on April 14, 2015. NLM Identifier: NCT02419456. Available at: https://www.clinicaltrials.gov/ct2/show/NCT02419456. Last accessed on January 31, 2018.
- Brown KC, Paul S, Kashuba AD. Drug interactions with new and investigational antiretrovirals. Clin Pharmacokinet. 2009;48(4):211-41. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2857544/. Last accessed on January 31, 2018.
- National Institute of Allergy and Infectious Diseases (NIAID). NIAID research on topical microbicides. Available at: http://www.niaid.nih.gov/topics/hivaids/research/prevention/pages/topicalmicrobicides.aspx. Last accessed on December 21, 2016.
- Shattock RJ, Rosenberg Z. Microbicides: Topical prevention against HIV. Cold Spring Harb Perspect Med. 2012 Feb;2(2):a007385. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3281595/. Last accessed on January 31, 2018.
- Strizki JM, Tremblay C, Xu S, et al. Discovery and characterization of vicriviroc (SCH 417690), a CCR5 antagonist with potent activity against human immunodeficiency virus type 1. Antimicrob Agents Chemother. 2005 Dec;49(12):4911-19. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1315929/. Last accessed on January 31, 2018.
- National Institutes of Health (NIH). NIH clinical research trials and you. Available at: https://www.nih.gov/health-information/nih-clinical-research-trials-you. Last accessed on January 31, 2018.
- Caseiro MM, Nelson M, Diaz RS, et al. Vicriviroc plus optimized background therapy for treatment-experienced subjects with CCR5 HIV-1 infection: final results of two randomized phase III trials. J Infect. 2012 Oct;65(4):326-35. Available at: https://www.ncbi.nlm.nih.gov/pubmed/22634184. Last accessed on January 31, 2018.
- Dunkle LM, Gathe J, Zhou H, McCarthy M. Antiviral effect of vicriviroc (VCV) plus ritonavir-boosted atazanavir (ATV/r) similar to tenofovir/emtricitabine (TEM) + ATV/r but efficacy (%<50c/mL) inferior as initial therapy. Abstract presented at: Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); September 12-15, 2010; Boston, MA. Abstract H-938a. Available at: http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=d89fb4da-4268-4d6b-88ee-4f4ebcd548de&cKey=bb11cf2f-7e42-4aa1-bffa-d364f8cc3e6d&mKey=%7b93AEED6A-54D4-4EF6-99BD-A9B3CE9FACD9%7d. Last accessed on January 31, 2018. [Archived at WebCite].
- Merck Sharp & Dohme Corp. Efficacy and Safety of VICRIVIROC in HIV-infected treatment-naive subjects. In: ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). Registered on October 29, 2007. NLM Identifier: NCT00551018. Available at: https://www.clinicaltrials.gov/ct2/show/NCT00551018. Last accessed on January 31, 2018.
- Merck Sharp & Dohme Corp. Vicriviroc in combination treatment with an optimized ART regimen in HIV-infected treatment-experienced subjects (VICTOR-E3). In: ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). Registered on August 30, 2007. NLM Identifier: NCT00523211. Available at: https://www.clinicaltrials.gov/ct2/show/NCT00523211. Last accessed on January 31, 2018.
- Merck Sharp & Dohme Corp. Vicriviroc in combination treatment with an optimized ART regimen in HIV-infected treatment-experienced subjects (VICTOR-E4). In: ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). Registered on May 15, 2007. NLM Identifier: NCT00474370. Available at: https://www.clinicaltrials.gov/ct2/show/NCT00474370. Last accessed on January 31, 2018.
- Mascolini M. Vicriviroc does not outdo placebo regimen in Phase 3 trials. Conference Reports for National AIDS Treatment Advocacy Project (NATAP): Conference on Retroviruses and Opportunistic Infections (CROI); February 16-19, 2010; San Francisco, CA. Available at: http://www.natap.org/2010/CROI/croi_12.htm. Last accessed on January 31, 2018. [Archived at WebCite]
Last Reviewed: January 31, 2018